Royce & Associates LP Has $748,000 Stake in AtriCure, Inc. (NASDAQ:ATRC)

Royce & Associates LP trimmed its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 62.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 24,482 shares of the medical device company’s stock after selling 40,303 shares during the period. Royce & Associates LP’s holdings in AtriCure were worth $748,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ATRC. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of AtriCure during the third quarter worth approximately $880,000. Commerce Bank lifted its holdings in AtriCure by 23.5% in the third quarter. Commerce Bank now owns 11,470 shares of the medical device company’s stock valued at $322,000 after buying an additional 2,181 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in AtriCure by 39.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 185,819 shares of the medical device company’s stock valued at $5,210,000 after buying an additional 52,533 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in AtriCure by 31.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock valued at $14,038,000 after buying an additional 119,929 shares during the period. Finally, Intech Investment Management LLC acquired a new position in AtriCure in the third quarter valued at approximately $427,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Trading Down 3.7 %

ATRC opened at $33.54 on Friday. The firm’s fifty day moving average is $38.22 and its two-hundred day moving average is $33.66. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The firm has a market cap of $1.64 billion, a PE ratio of -35.30 and a beta of 1.53. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11.

Insider Transactions at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares of the company’s stock, valued at $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on ATRC. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 13th. JMP Securities restated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. Canaccord Genuity Group increased their price objective on shares of AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Piper Sandler increased their price objective on shares of AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $51.00 price objective on shares of AtriCure in a report on Friday. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.